StockData
Treace Medical Concepts, Inc. logo

Treace Medical Concepts, Inc. (TMCI) company profile

TMCINasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/3031% below fair value
$4.44+0.02 (+0.45%)

Close on Nov 17, 2026Market cap $288.75MP/E –Yield –

About Treace Medical Concepts

Surgical & Medical Instruments & Apparatus, SIC 3841

Treace Medical Concepts, Inc. is a medical technology company focused on advancing surgical treatments for bunions and related midfoot deformities. The company's primary offering is the Lapiplasty 3D Bunion Correction System, which combines specialized instruments, implants, and surgical methods to correct bunion deformities in three planes. Its portfolio also features the Adductoplasty Midfoot Correction System, the Nanoplasty and Percuplasty systems for minimally invasive osteotomies, the SpeedMTP System for great toe fusions, and IntelliGuide pre-operative planning software and cutting guides. Treace Medical Concepts markets these systems to surgical podiatrists, orthopaedic foot and ankle surgeons, ambulatory surgery centers, and hospitals.

The company operates in the United States, utilizing a direct employee sales force alongside independent sales agencies. Its commercial outreach targets approximately 8,000 surgical podiatrists and 2,600 orthopaedic foot and ankle specialists across the country. Treace Medical Concepts is headquartered in Ponte Vedra, Florida.

Summary of the business section of Treace Medical Concepts's latest annual report, written by StockData.

Company profile

Company

Legal name
Treace Medical Concepts, Inc.
Headquarters
Ponte Vedra, FL
Address
100 Palmetto Park Place 32081
Phone
(904) 373-5940
Website
treace.com
Employees
450, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Florida
Fiscal year ends
December 31
Auditor
GRANT THORNTON LLP, Jacksonville, Florida

Stock & identifiers

Ticker
TMCI
Exchange
Nasdaq
IPO date
Apr 26, 2021
Shares outstanding
65M, Jul 31, 2026
Public float
$265.90M, Jun 30, 2025
Filer category
Accelerated filer
SEC CIK
1630627
CUSIP
89455T109
ISIN
US89455T1097
FIGI
BBG00GQKR6M4
Share class FIGI
BBG00GQKR6N3
EIN
47-1052611

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
John T. TreaceChief Executive Officer, Director12,728,512
Sean F. ScanlanChief Innovation Officer634,656
Scot Michael ElderChief Legl & Comp Off, CorpSec753,226
Mark HairChief Financial Officer916,100
Gaetano GuglielminoChief Commercial Officer490,901
Aaron BeruttiSVP, Sales205,092
Deepti JainDirector100,243
Lawrence W. HamiltonDirector74,056
John K. BakewellDirector546,356
Lance A. BerryDirector74,593
Betsy HannaDirector75,243
Jane E. KiernanDirector93,949
Richard W. MottDirector1,498,111

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$5.41M-$246.43K$3.06M$13$76
FY2024$6.60M$1.14M$3.84M$40$76
FY2023$8.42M$2.84M$3.97M$68$72
FY2022$3.62M$4.32M$1.48M$123$77

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOtherTotalvs. prior year
John T. Treace
Chief Executive Officer, Founder and Board Chair
$755.35K$4.64M$14.84K$5.41M-18%
Mark L. Hair
Chief Financial Officer
$509.96K$4.63M$14.84K$5.16M+15%
Scot M. Elder
Chief Legal & Compliance Officer, Corporate Secretary
$432.10K$1.68M$14.84K$2.12M-53%
Sean F. Scanlan
Chief Innovation Officer
$446.37K$1.85M$14.84K$2.31M-25%
Gaetano M. Guglielmino
Chief Commercial Officer
$440.00K–$28.54K$468.54K-85%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Apr 26, 2021
Offer price
$17.00
Securities offered
11,250,000
Gross proceeds
$191.25M
Exchange
Nasdaq
Lock-up ends (est.)
Oct 23, 2021

“The initial public offering price is $17.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had approximately 450 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?